Share This Page
Drugs in ATC Class D11AA
✉ Email this page to a colleague
Drugs in ATC Class: D11AA - Antihidrotics
| Tradename | Generic Name |
|---|---|
| GLYCOPYRRONIUM TOSYLATE | glycopyrronium tosylate |
| QBREXZA | glycopyrronium tosylate |
| SOFDRA | sofpironium bromide |
| >Tradename | >Generic Name |
ATC D11AA Antihidrotics market dynamics and patent landscape: Glycopyrronium, oxybutynin, botulinum toxin and iontophoresis
ATC Class D11AA (antihidrotics) is split between (1) topical and transdermal anticholinergics used to suppress sweating, (2) procedural and device-based therapies, and (3) botulinum toxin products for focal hyperhidrosis. Patent and exclusivity risk is concentrated in branded active ingredients and delivery systems, with meaningful whitespace on formulation, dosing regimens, and patient-setup claims for devices and botulinum toxin usage. In the US, product-specific Orange Book listings are the main driver of generic entry timing for small-molecule antihidrotics; for botulinum toxin, exclusivity hinges on biologic licensing strategy and device/procedure IP around administration rather than classical small-molecule Orange Book dynamics.
What patents protect D11AA antihidrotics products (and how many are there)?
The D11AA antihidrotics category does not map to a single patent cluster. Protection typically spans:
- Active ingredient composition (anticholinergic, antisecretory actives).
- Delivery system patents (topical vehicle, transdermal patches, controlled-release matrices).
- Method-of-use patents (treatment of primary focal hyperhidrosis, palmar/axillary indications, sweat reduction endpoints).
- Device and workflow patents for iontophoresis and temperature/current delivery.
- Biologic protein and manufacturing patents for botulinum toxin products, plus administration and patient-selection claims.
Which active ingredients and technologies dominate D11AA?
Common commercial and development groupings for antihidrotics include:
- Topical/transdermal anticholinergics: glycopyrronium salts (topical and transdermal), oxybutynin derivatives (including gels/solutions in some markets), and related muscarinic antagonists.
- Botulinum toxin (type A formulations): used for focal hyperhidrosis with extensive product and manufacturing IP estates across geographies.
- Devices: iontophoresis systems are governed by device claims, electrode designs, power/current profiles, and software control.
Patent density tends to concentrate in delivery and regimen claims
Across the category, the largest “switching cost” for competitors is usually not the underlying molecule, but:
- optimized vehicle composition that improves skin penetration and tolerability,
- patch/controlled-release architecture for sustained sweat suppression,
- treatment regimens specifying frequency, duration, and anatomical dosing.
How strong is the patent estate for D11AA antihidrotics (topical anticholinergics vs botulinum toxin vs devices)?
Patent strength in D11AA typically diverges by modality:
Topical/transdermal anticholinergics
Strength is often high where there is:
- a branded development program for a specific salt, concentration, and delivery vehicle,
- multiple continuation applications covering both composition and method-of-use.
Key watchpoints are:
- whether the molecule’s core patent has already expired in target jurisdictions,
- whether delivery-system and regimen claims still have term left,
- whether a competitor can design around by using a different vehicle, penetration enhancer, patch matrix, or dosing protocol.
Botulinum toxin
Strength tends to be high due to:
- layered protection on formulation, manufacturing, stability, and protein characterization,
- biologic process patents,
- administration and dosing-pattern claims that can constrain substitution.
Entry paths are less about “generic equivalence” and more about:
- clinical interchangeability,
- regulatory approval strategy,
- procurement and payer contracting barriers.
Devices (iontophoresis)
Strength is concentrated in:
- electrode arrangements and current delivery schemes,
- safety interlocks and patient interface,
- algorithmic control of intensity ramps and dwell times.
Because devices are not governed by Orange Book timing, the risk for market entrants is more about design-around feasibility and procedural claim exposure than about patent expiration calendars alone.
When does D11AA antihidrotics lose exclusivity (US and EU) for major brand drivers?
Featured-snippet answer: exclusivity loss in D11AA is not uniform by molecule because delivery systems and dosing regimens frequently carry later-dated protection than the base active ingredient.
US dynamics
- Small-molecule antihidrotics with FDA approvals typically show up in the Orange Book.
- Generic entry risk is tied to:
- patent expiration dates listed in the Orange Book,
- whether the generic applicant files Paragraph IV certifications,
- whether litigation triggers the statutory stay.
EU dynamics
- EU exclusivity typically involves:
- supplementary protection certificates (SPCs) and national patent enforceability,
- data exclusivity and market protection rules by product type,
- separate national enforcement timelines for formulation versus method patents.
Botulinum toxin and devices
- Botulinum toxin entry and competitive substitution is paced by biologics authorization and IP layering, not Orange Book listings.
- Device exclusivity is determined by patent claim coverage and design-around capability.
What is the Orange Book status of D11AA antihidrotics products (and which patents list there)?
Featured-snippet answer: Orange Book status is product-specific; D11AA as a class cannot be treated as a single Orange Book dataset because multiple active ingredients and modalities are in scope.
For decision-grade analysis, the Orange Book “risk surface” should be mapped by:
- NDA/BLA product,
- listed patents (composition, formulation, method-of-use),
- expiration and any listed pediatric exclusivity extensions,
- whether listed patents include formulation or only basic active ingredient claims.
Which companies are challenging D11AA antihidrotics patents (Paragraph IV and litigation patterns)?
In D11AA, the practical challenge set usually clusters into two buckets:
- Topical/transdermal anticholinergic generics: firms that can match the delivery mechanism or design around by altering formulation or regimen.
- Procedural substitution: entrants around botulinum toxin and devices where claims focus on dosing patterns and device workflow.
Paragraph IV filings, where they exist, are typically used to accelerate approval and price competition, but success depends on:
- which Orange Book patents are asserted and held,
- whether courts find a claim invalid or not infringed,
- whether a settlement limits launch dates.
What patent litigation affects antihidrotics in D11AA (and how does it change launch timing)?
Featured-snippet answer: for D11AA small-molecules, litigation changes timing through Orange Book stay mechanics and settlement launch caps. For botulinum toxin and devices, litigation shifts design choices and limits substitution rather than forcing regulatory-dated entry windows.
Key litigation outcomes to model:
- early dismissal or claim invalidation leading to faster generic substitution,
- “carve-out” settlements that allow approval but delay commercial launch,
- court rulings that narrow infringement scope to specific formulation or dosing conditions.
What formulations are protected by D11AA antihidrotics patents (vehicle, patch matrix, concentration)?
Patent coverage often specifies:
- concentrations and ratios of active to excipients,
- skin penetration enhancers and surfactant systems,
- viscosity, rheology modifiers, and film-formers,
- patch membrane architecture and controlled-release matrices.
Common formulation claim themes
- Vehicle claims: proprietary semisolid base or hydrogel matrix that improves distribution to sweat glands.
- Controlled release: rate-controlling polymers and diffusion barriers.
- Stability claims: shelf-life and stability under temperature and light exposure.
- Use claims tied to anatomic sites: axillary versus palmar regimens.
What method-of-use patents matter most for D11AA antihidrotics (axillary vs palmar, dosing regimens, endpoints)?
Featured-snippet answer: method-of-use coverage often drives practical exclusivity even after composition patents expire because it constrains dosing frequency and target indications.
Common claim patterns include:
- treatment of primary axillary hyperhidrosis with defined dosing schedules,
- palmar or plantar treatment regimens with exposure-limiting instructions,
- sweat reduction endpoints operationalized in clinical trial frameworks.
How does ATC D11AA antihidrotics compare with other hyperhidrosis categories (treatments beyond anticholinergics)?
D11AA competes with:
- systemic oral anticholinergics used off-label in some markets,
- botulinum toxin for focal hyperhidrosis,
- procedural approaches such as microwave therapy, curettage, or endoscopic thoracic sympathectomy.
The patent landscape varies:
- systemic therapies face different IP estates tied to oral formulations and dosing,
- botulinum toxin is biologic IP-heavy,
- procedures are dominated by practitioner technique and device/procedure patents.
What generic entry risks exist for D11AA antihidrotics (design-around feasibility and infringement triggers)?
Generic entry risks are driven by:
- Delivery-system similarity: if the branded product uses a unique penetration-enhancing vehicle or controlled release matrix, “same active, different formulation” may still be found to infringe depending on claim language.
- Regimen lock-in: method-of-use claims can force labeling or off-label restrictions even if composition patents are avoided.
- Patent claim breadth: broad genus claims covering classes of excipients are harder to design around than narrow exemplified formulations.
- Manufacturing process patents: less visible but can constrain scalability and lead to licensing requirements.
Where are the biggest commercial risks and upside for D11AA antihidrotics (payers, formulary, and switching)?
Commercial dynamics in D11AA hinge on:
- payer preference for branded versus compounded topical products,
- tolerability and adverse event profiles driving step therapy,
- switching costs from device-based therapy to topical regimens or vice versa.
Patent outcomes translate to:
- margin compression at launch once exclusivity ends,
- increased channel mix volatility when new entrants can undercut branded pricing.
Key comparison: What differentiates patent estates across D11AA modalities?
| Modality | Typical dominant IP | Main competitive threat | What usually expires last |
|---|---|---|---|
| Topical/transdermal anticholinergics | composition + formulation + method-of-use | generic/same-API topical competitors | delivery system and regimen patents |
| Botulinum toxin | biologic product + manufacturing + administration | biosimilar/alternate product procurement | administration/dosing constraints and biologic patent layering |
| Iontophoresis devices | device structure + control software + workflow | device OEMs and platform substitutions | safety and control algorithms claims |
Key timelines model for D11AA launches (how to forecast entry windows)
A reliable entry forecast for D11AA depends on building a timeline by product, then layering:
- Patent expirations (composition/formulation/method).
- Regulatory exclusivities tied to FDA approval type (data exclusivity, market exclusivity where applicable).
- Orange Book listed patents (for small molecules): identify which patents actually block approval.
- Litigation/settlements: any stay triggers or negotiated launch dates.
- Design-around pathways: whether generic challengers can avoid infringement while maintaining bioequivalence and clinical positioning.
Key Takeaways
- ATC D11AA antihidrotics is fragmented by modality; exclusivity and competitive risk are driven by delivery system and method-of-use patents for anticholinergic products, biologic and administration IP for botulinum toxin, and device workflow/control claims for iontophoresis.
- Orange Book status is product-specific and must be mapped by NDA/BLA to identify the real launch blockers for small-molecule antihidrotics.
- The last-to-expire layer across the class is usually formulation and dosing-regimen protection, which meaningfully affects generic design-around and launch timing.
- Litigation and settlements change real-world launch calendars through Orange Book stays for small molecules and through practical substitution constraints for biologics and devices.
FAQs
- Which patent claim types most often block generic topical antihidrotics entry in the US?
- How do method-of-use patents for axillary hyperhidrosis affect labeling and generic substitution?
- Are iontophoresis device patents easier to design around than topical formulation patents?
- Do botulinum toxin exclusivity timelines behave like small-molecule Orange Book exclusivity?
- What settlement terms most commonly cap launch dates for antihidrotics challengers?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Therapeutic Equivalence and Patent Certifications (Paragraph IV framework). U.S. Food and Drug Administration. https://www.fda.gov/
More… ↓
